HIV-AIDS vaccine will be available in the nearest future
According to information made available by canadian media recently, researchers are now heading towards a vaccine.
« A potential first and only preventative HIV vaccine, developed by Dr. Chil-Yong Kang and his team at The University of Western Ontario, has received approval by the United States Food and Drug Administration (USFDA) to start human clinical trials this month south of the border. With the support of Sumagen Canada, and based on a genetically modified killed whole virus, the vaccine holds tremendous promise, having already proven to stimulate strong immune responses in preliminary toxicology tests with no adverse effects or safety risks.
With the USFDA holding the most stringent approval requirements, Kang chose to go this route with the only HIV vaccine currently under development in Canada – and one of only a few in the world. “FDA approval for human clinical trials is an extremely significant milestone for our vaccine, which has the potential to save the lives of millions of people around the world by preventing HIV infection,” says Kang, a researcher and professor at Western’s Schulich School of Medicine & Dentistry. HIV/AIDS has killed more than 28 million people worldwide, and more than 35 million people currently live with the virus. Since the virus was first characterized in 1983, there have been numerous trials through pharmaceutical companies and academic institutions around the world to develop vaccines; however, no commercialized vaccine has been developed to date. Other vaccines evaluated through human clinical trials have focused on either one specific component of HIV as an antigen, genetic vaccine using recombinant DNA, or recombinant viruses carrying the HIV genes. Kang’s vaccine is unique in that it uses a killed whole HIV-1, much like the killed whole virus vaccines for polio, influenza, rabies and hepatitis A. The HIV-1 is genetically engineered so it is non-pathogenic and can be produced in large quantities. “This joint venture between Sumagen and Western is a prime example of what collaboration between private industry and university researchers can achieve,” says Western president Amit Chakma. “Dr. Kang and his team are to be commended for their
exceptional talent and remarkable persistence in developing a vaccine that addresses a tragic health crisis affecting millions of people around the globe.”» (Source: Western News, 05 Jan.2012. The entire text is available at the following link: hiv-vaccine-heads-to-human-clinical-trials)
Any African reader of this information may ask himself several questions regarding the attitude of the scientific community. Indeed, since several years, a (late) Cameroon researcher, Professor Victor Anomah Ngu declared to have invented a vaccine. He also called for open confrontation with the scientific community and to a public evaluation of his vaccine. It is really surprising that no particular attention has been paid to his discoveries so far. After the publication of the FDA’s decision authorizing the Canadian research team to carry on testings on humans, we contacted Prof. Anomah Ngu’s team in Yaoundé (Cameroun) with the intention to learn more about the state of their research and particularly about the originality of the Canadians’ discouveries when compared to their vacinne Vanhivax. We have received no answer from the Camerounian research team.
About Vahnivax, following information could be read from the website of Prof. Anomah Ngu’s Clinic:
Vanhivax is not a drug so the virus cannot become resistant to it. The auto-vaccine is elaborated from the blood of each individual patient.
Because the vaccine is not toxic, there are no significant side effects (ie—damage to the organic body). A mild fever, headache, or tenderness in the area of the injection is all one is likely to experience. Whereas the virus increases in strength with the drugs over time, the auto-vaccination treatment of Vanhivax strengthens the immune system against HIV.
Vanhivax seeks to create a healthy immune system, based on the body’s own defenses. In most cases the body can then mount an effective immune response against the virus. It’s the body’s own perfect medicine.
Since every organism reacts differently, the dosage of Vanhivax varies greatly. As Dr. Bisong of the Clinic says, “The vaccine is like a train rolling down its tracks. It has its own momentum, its own power, and if you give the patient an extra dose of the vaccine, it could derail the whole process. Most people want as many treatments as possible but the body and the vaccine don’t work that way.”
Victor Anomah Ngu / Founder of the Clinic of Hope:
Now, as far as Vanhivax is concerned and the virus, the vaccine does not act on the virus directly. It doesn’t. It acts on the immune system and the immune system then acts on the virus. »
For details on the researches of late Prof. Victor Anomah Ngu:
Clinique de L’Espoir.
BP. 11775, Yaounde, Cameroon
Telephone: +237 222 4189
Tel/Fax +237 220 2786
Web: www.cellularwisdom.org
Contact us: cellularwisdom.org@gmail.com
Cameroun: Le Choléra tue encore ! 1500 morts en 20 mois Bourses pour Stage en gestion des systèmes de services de santé – économie et planification des systèmes de santé
Comments are currently closed.